Renovorx announces presentation at symposium on clinical interventional oncology (cio) highlighting its innovative therapy platform for targeted treatment of pancreatic cancer

Los altos, calif.--(business wire)--renovorx, inc. (nasdaq: rnxt), a biopharmaceutical company focused on the localized treatment of difficult-to-treat solid tumors through its proprietary renovorx trans-arterial micro-perfusion (renovotamptm) therapy platform, today announced ripal gandhi, m.d., fsir, fsvm presented, “trans-arterial micro-perfusion therapy for pancreatic cancer,” at the recent symposium on clinical interventional oncology (cio). dr. gandhi is a course director for the symposiu
RNXT Ratings Summary
RNXT Quant Ranking